Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy

Authors

  • David Berd MD,

    Postdoctoral Fellow, Corresponding author
    1. Department of Internal Medicine, Section of Medical Oncology, Yale-New Haven Hospital, New Haven, CT
    • Department of Internal Medicine, Section of Medical Oncology, Yale-New Haven Hospital, 333 Cedar St., New Haven, CT 06510
    Search for more papers by this author
  • John Cornog MD,

    Associate Professor of Pathology
    1. Department of Internal Medicine, Section of Medical Oncology, Yale-New Haven Hospital, New Haven, CT
    Search for more papers by this author
  • Ronald C. Deconti MD,

    Director of Oncology
    1. Department of Internal Medicine, Section of Medical Oncology, Yale-New Haven Hospital, New Haven, CT
    Search for more papers by this author
    • Springfield Hospital, Springfield, MA.

  • Martin Levitt MD,

    Assistant Professor
    1. Department of Internal Medicine, Section of Medical Oncology, Yale-New Haven Hospital, New Haven, CT
    Search for more papers by this author
    • Dept. of Medicine, University of Manitoba, Winnipeg, Canada.

  • Joseph R. Bertino MD

    Professor of Medicine and Pharmacology
    1. Department of Internal Medicine, Section of Medical Oncology, Yale-New Haven Hospital, New Haven, CT
    Search for more papers by this author

  • Presented at the 10th Annual Meeting of the American Society of Clinical Oncology, Houston, TX, March 27–28, 1974.

Abstract

Seventeen patients with Stage III or IV reticulum cell sarcoma were treated with three cycles of a 5-drug regimen between February, 1969 and December, 1970. Of the 17 patients, 9 attained a complete remission and 6 had a partial remission; 2 were considered unevaluable. Recently, the original biopsies from these patients were reclassified according to the criteria of Rappaport et al.7 The results were: diffuse histiocytic—8; nodular histiocytic—2; diffuse mixed—2; nodular mixed—3; diffuse lymphocytic poorly differentiated—1; nodular lymphocytic poorly differentiated—1. Of the 8 patients with diffuse histiocytic lymphoma 6 attained complete remission, 1 had a partial remission, and 1 was unevaluable. One of the 6 with complete remission relapsed at 7 months and died 2 months later. However, the other 5 are alive and in continued unmaintained remission for 55 to 65 months.

Ancillary